Bing Wang trained as an electrical engineer, but his experience as a cancer survivor led him into the world of healthcare investment banking and then to his current role as CEO of the cancer therapeutics company Refuge Biotechnologies. Refuge is leveraging CRISPR technology, but rather than editing genes, the company is using it as a way to activate or inhibit specific genes by harnessing it for its targeting mechanism. We spoke to Wang about his own journey from patient to CEO, the company’s technology, and why he believes this will lead to safer and more effective cancer therapies.